IGC Pharma Annonuces Mouse Studies Showing Reduction In Amyloid Plaque With TGR-63: 78% In Cortex And 85% In Hippocampus
Portfolio Pulse from Benzinga Newsdesk
IGC Pharma announced that its drug candidate TGR-63 showed significant reduction in amyloid plaque in mouse studies, with a 78% reduction in the cortex and 85% in the hippocampus.
June 25, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IGC Pharma's drug candidate TGR-63 demonstrated significant reduction in amyloid plaque in mouse studies, which could be a positive indicator for future clinical trials and potential market approval.
The significant reduction in amyloid plaque in preclinical studies is a positive development for IGC Pharma, potentially boosting investor confidence and stock price in the short term as it indicates progress in their drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100